The role of real-world evidence (RWE) in regulatory, drug development, and healthcare decision-making is rapidly expanding. Recent advances have increased the complexity of cancer care and widened the gap between randomized clinical trial (RCT) results and the evidence needed for real-world clinical decisions. Instead of remaining invisible, data from the >95% of cancer patients treated outside of clinical trials can help fill this void.
No takes yet. Share an insight, caveat, or question.
Miksad et al. (2017) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: